Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Rating Lowered by StockNews.com

StockNews.com downgraded shares of Adaptimmune Therapeutics (NASDAQ:ADAP) from a strong-buy rating to a buy rating in a report released on Thursday.

Separately, HC Wainwright decreased their target price on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a research note on Thursday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $3.16.

Adaptimmune Therapeutics Trading Down 0.8 %

Adaptimmune Therapeutics stock opened at $0.59 on Thursday. The company has a market capitalization of $150.02 million, a price-to-earnings ratio of -2.67 and a beta of 2.26. The company’s fifty day moving average price is $0.88 and its two-hundred day moving average price is $1.03. Adaptimmune Therapeutics has a one year low of $0.42 and a one year high of $2.05. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.09.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ADAP. Long Focus Capital Management LLC boosted its position in shares of Adaptimmune Therapeutics by 15.6% during the 2nd quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company’s stock valued at $12,037,000 after acquiring an additional 1,662,184 shares in the last quarter. Baillie Gifford & Co. lifted its stake in Adaptimmune Therapeutics by 10.7% during the third quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock worth $15,944,000 after purchasing an additional 1,626,657 shares during the period. Renaissance Technologies LLC boosted its holdings in Adaptimmune Therapeutics by 28.3% during the second quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock valued at $1,742,000 after purchasing an additional 394,566 shares in the last quarter. Vontobel Holding Ltd. grew its stake in shares of Adaptimmune Therapeutics by 230.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 30,000 shares during the period. Finally, Fullcircle Wealth LLC bought a new stake in shares of Adaptimmune Therapeutics in the 3rd quarter valued at approximately $33,000. Institutional investors own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.